Medtronic is considered a 'Buy' due to its undervalued stock, recent product launches, and resolved supply chain issues. Despite underperformance, it posted solid Q2 results with a 5.25% YoY revenue increase and expects 4.75%-5% organic revenue growth for fiscal 2025. Strategic acquisitions and innovation are expected to drive growth and improve margins.